🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The Christie NHS is an approved Centre for the ESO fellowship programme. If you are motivated and want to sub specialise in thoracic malignancies, look at the ESO website for details.I can host you for a 6 months fellowship, from Jan '25 SEOM BTOG eso.net/en/what-we-do/…

ft.com/content/f6972d…

#WEAREVESPUCCI

Correlation between irAEs and Survival Outcomes in Patients with ES-SCLC Treated with First-Line Chemoimmunotherapy led by F Monaca sciencedirect.com/science/articl… Igor Fiona Blackhall Christie Library Division of Cancer Sciences Fabio Gomes

Please see our review paper on the Evolving treatment for advanced Non-small cell lung cancer harbouring common EGFR activating mutations. Led by Igor, in collaboration with d.planchard sciencedirect.com/science/articl… Christie Library EGFR Resisters BTOG ESMO - Eur. Oncology EGFR Positive Lung Cancer UK

Open access & up to date review of immunotherapy for earlier stage lung cancer led by Dr. ⁦Colum Dennehy chief fellow ⁦Johns Hopkins Hematology and Oncology Fellowship⁩ & an all 🇮🇪 team out now! ⁦Trinity St James's Cancer Institute⁩ “Immunotherapy for resectable lung cancer” - Cancer acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

The Lung Team at The Christie Is conducting trials in the first line setting for untreated patients with extensive stage (advanced) small cell lung cancer. Contact [email protected] to find out more SmallCellSMASHERS BTOG Roy Castle Lung Cancer Foundation

The ALKnowledge.org is now LIVE with both the patients and HCP module! vimeo.com/1071193328/7e6…

Thank you to Raffaele Califano of The Christie NHS for joining us at #ASCO25 to discuss amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced #lcsm after disease progression on osimertinib. Check back at onclive.com for the full interview.

#ASCO25 A very informative poster focusing on ami+chemo efficacy outcomes in MARIPOSA2 based on plasma-detected mechanisms of resistance to osi , by great Raffaele Califano . Efficacy of the combo independent of MET amplif as a MoR or presence of TP53 mut #LCSM #some ASCO

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer | New England Journal of Medicine nejm.org/doi/full/10.10… Patrick Forde

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy | New England Journal of Medicine nejm.org/doi/full/10.10… @

ascopost.com/videos/2025-as… Here is a summary of our findings for the Mariposa 2 trial analysis reported at #ASCO25 BTOG EGFR Positive Lung Cancer UK EGFR Resisters

Proud to be part of the IMforte effort - the first phase 3 maintenance study in #SCLC to show a survival benefit with an OS HR 0.73 - grateful to the team Luis Paz-Ares Hossein Borghaei, DO Solange Peters Roy Herbst Melissa L. Johnson Raffaele Califano Martin Reck thelancet.com/journals/lance…

It is an absolute pleasure to have been able to treat Jeff!